Evidence mapPaperPMID 36778595Full record

Trial reportFrontiers in endocrinology2022

Novel nutraceutical supplements with yeast β-glucan, prebiotics, minerals, and

Victor Nehmi-Filho, Aline Boveto Santamarina, Jéssica Alves de Freitas, Ericka Barbosa Trarbach, Daniela Rodrigues de Oliveira, Fanny Palace-Berl, Erica de Souza, Danielle Araujo de Miranda, Antonio Escamilla-Garcia, José Pinhata Otoch and 1 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07038135 (Formulation, Phytochemical Characterization, and Clinical Assessment of a Novel Natural Supplement Targeting Body Composition in Physically Active Individuals), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07038135 nacompletednot on this mapstarted 2024, after this paper: background citation

Formulation, Phytochemical Characterization, and Clinical Assessment of a Novel Natural Supplement Targeting Body Composition in Physically Active Individuals: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

TypeinterventionalSponsorSulaimani Polytechnic UniversityRan2024 to 2025Enrolled65ConditionsImproving Body Composition, Novel Natural Gym Nutrient Formulation, Increase Muscle Mass, Reduce Body Fat PercentageArmsNovel Natural Supplement (NNS), Placebo
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Postbiotics fromNutrients · 2025
    Article
  7. Review
  8. Article
  9. Effect of alpha-lipoic acid andWorld journal of hepatology · 2025
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Silymarin Reduced Insulin Resistance in Non-Diabetic Women with Obesity.International journal of molecular sciences · 2024
    Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Victor Nehmi-FilhoNatural Products and Derivatives Laboratory (LIM-26), Department of Surgery, University of São Paulo Medical School, São Paulo, SP, Brazil.
Aline Boveto SantamarinaDepartment of Biosciences, Federal University of São Paulo (UNIFESP), Santos, SP, Brazil.
Jéssica Alves de FreitasNatural Products and Derivatives Laboratory (LIM-26), Department of Surgery, University of São Paulo Medical School, São Paulo, SP, Brazil.
Ericka Barbosa TrarbachLaboratory of Cellular and Molecular Endocrinology (LIM25), Division of Endocrinology and Metabology, Clinics Hospital, University of São Paulo Medical School, São Paulo, SP, Brazil.
Daniela Rodrigues de OliveiraNatural Products and Derivatives Laboratory (LIM-26), Department of Surgery, University of São Paulo Medical School, São Paulo, SP, Brazil.
Fanny Palace-BerlNatural Products and Derivatives Laboratory (LIM-26), Department of Surgery, University of São Paulo Medical School, São Paulo, SP, Brazil.
Erica de SouzaMonte Azul Ambulatory, São Paulo, SP, Brazil.
Danielle Araujo de MirandaDepartament of Physiology, Escola Paulista de Medicina/Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Antonio Escamilla-GarciaUniversity Hospital of the University of São Paulo, University of São Paulo Medical School, São Paulo, SP, Brazil.
José Pinhata OtochNatural Products and Derivatives Laboratory (LIM-26), Department of Surgery, University of São Paulo Medical School, São Paulo, SP, Brazil.
Ana Flávia Marçal PessoaNatural Products and Derivatives Laboratory (LIM-26), Department of Surgery, University of São Paulo Medical School, São Paulo, SP, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: It is known that obesity has a multifactorial etiology that involves genetic and environmental factors. The WHO estimates the worldwide prevalence of 1.9 billion overweight adults and more than 650 million people with obesity. These alarming data highlight the high and growing prevalence of obesity and represent a risk factor for the development and aggravation of other chronic diseases, such as nonalcoholic fatty liver disease (NAFLD) that is frequently considered the hepatic outcome of type 2 diabetes. The use of non-pharmacological therapies such as food supplements, nutraceuticals, and natural integrative therapies has grown as an alternative tool for obesity-related diseases compared to conventional medications. However, it is a still little explored research field and lacks scientific evidence of therapeutic effectiveness. Considering this, the aim is to evaluate whether a new nutraceutical supplement composition can improve and supply essential mineral nutrients, providing an improvement of obesity-related metabolic and endocrine parameters. Methods: Sedentary volunteers (women and men) with body mass index (BMI) ≤34.9 kg/m Results: In the anthropometric analysis, the waist circumference in middle abdomen (WC-mid) and waist circumference in iliac crest (WC-IC) were reduced. Also, the waist-to-height ratio (WHt R) and waist-to-hip ratio (WHR) seem to slightly decrease alongside the supplementation period with both nutraceutical supplements tested as well as transaminase enzyme ratio [aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio (AAR)], a known as a biomarker of NAFLD, and endocrine hormones cortisol and thyroid-stimulating hormone (TSH) at 90 and 180 days post-supplementation. Conclusions: In a condition associated with sedentary and no nutritional intervention, the new nutraceutical supplement composition demonstrated the ability to be a strong and newfangled tool to improve important biomarkers associated with obesity and its comorbidities.

Indexed as

beta-GlucansDiabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseSilymarinAdultBiomarkersDietary SupplementsFemaleHumansMaleMineralsObesityPrebioticsSaccharomyces cerevisiaeSilybum marianumbeta-GlucansBiomarkersMineralsPrebioticsSilymarinendocrine parametersnutraceuticsobesityprebioticSilybum marianumsupplementtransaminases

Identifiers

PMID36778595
PMCPMC9912840

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.